Publications in collaboration with researchers from KU Leuven (7)

2021

  1. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data

    Blood Advances, Vol. 5, pp. 5098-5106

  2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

    European Journal of Cancer, Vol. 148, pp. 411-421

  3. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study*

    British Journal of Dermatology, Vol. 184, Núm. 3, pp. 524-531

  4. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*

    British Journal of Dermatology, Vol. 184, Núm. 4, pp. 722-730

2020

  1. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

    European Journal of Cancer, Vol. 133, pp. 120-130

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

2006

  1. Gene expression profiling of primary cutaneous melanoma and clinical outcome

    Journal of the National Cancer Institute, Vol. 98, Núm. 7, pp. 472-482